Loading...
Header Logo
Keywords
Last Name

Steven Mark Sorscher, M.D.

TitleProfessor
InstitutionWake Forest School of Medicine
DepartmentInternal Medicine - Hematology and Oncology
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Sorscher S. Rationale for evaluating breast cancers of Lynch syndrome patients for mismatch repair gene expression. Breast Cancer Res Treat. 2019 Aug 07. PMID: 31392519.
      View in: PubMed
    2. Sorscher S. Molecular Markers of Molecular Markers. J Clin Oncol. 2019 Jul 03; JCO1900746. PMID: 31268797.
      View in: PubMed
    3. Sorscher S. Quantitative mRNA Expression Assays and Synchronous Breast Cancers: A Case Report. Case Rep Oncol. 2019 May-Aug; 12(2):418-420. PMID: 31244644.
      View in: PubMed
    4. Amin M, Desai M, Trinkaus K, Brown A, Wang-Gillam A, Tan B, Picus J, Sorscher S, Highkin M, Lears K, Lockhart AC. Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer. J Gastrointest Oncol. 2019 Jun; 10(3):412-420. PMID: 31183190.
      View in: PubMed
    5. Sorscher S. Circulating cell-free DNA use for diagnosing cholangiocarcinoma. Clin Epigenetics. 2019 May 14; 11(1):75. PMID: 31088529.
      View in: PubMed
    6. Sorscher S. Universal Multigene Panel Testing in all Breast Cancer Patients. Am J Med. 2019 Apr 01. PMID: 30946833.
      View in: PubMed
    7. Sorscher S. Analytical Validity and Clinical Utility of Tumor Biomarkers. JAMA Oncol. 2018 Oct 01; 4(10):1432. PMID: 30027205.
      View in: PubMed
    8. Sorscher S. Prognosis of patients with multifocal breast cancer. Hum Pathol. 2019 Feb; 84:335. PMID: 30267778.
      View in: PubMed
    9. Sorscher S. Letter to the Editor: Significance of Clonal Hematopoiesis of Indeterminate Potential. J Natl Compr Canc Netw. 2018 Sep; 16(9):1032-1033. PMID: 30181414.
      View in: PubMed
    10. Sorscher S. Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies. JAMA Oncol. 2018 Sep 01; 4(9):1299-1300. PMID: 29978198.
      View in: PubMed
    11. Sorscher S. Should adjuvant chemotherapy be recommended to a 75-year-old woman with deficient mismatch repair (dMMR) gene product expression seen in a stage II colon adenocarcinoma with lymphovascular invasion? Curr Probl Cancer. 2018 11; 42(6):601-604. PMID: 30119912.
      View in: PubMed
    12. Sorscher S. The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations. Oncologist. 2018 Nov; 23(11):1266-1268. PMID: 29866945.
      View in: PubMed
    13. Sorscher S. Ascertainment Bias and Estimating Penetrance. JAMA Oncol. 2018 04 01; 4(4):587. PMID: 29285541.
      View in: PubMed
    14. Sorscher S. Expanding definitions of HER2 positivity. Mod Pathol. 2018 04; 31(4):685. PMID: 29666481.
      View in: PubMed
    15. Waqar SN, Boehmer L, Morgensztern D, Wang-Gillam A, Sorscher S, Lawrence S, Gao F, Guebert K, Williams K, Govindan R. Immunogenicity of Influenza Vaccination in Patients With Cancer. Am J Clin Oncol. 2018 03; 41(3):248-253. PMID: 26669741.
      View in: PubMed
    16. Sorscher S. Clinical Trials in Oncology and Defining Benefit. Oncologist. 2018 01; 23(1):135. PMID: 29133517.
      View in: PubMed
    17. Sorscher S. Mutation Frequencies in Patients With Early-Onset Colorectal Cancer. JAMA Oncol. 2017 11 01; 3(11):1585. PMID: 28687829.
      View in: PubMed
    18. Sorscher S. Reclassifying HER2-equivocal disease. Breast Cancer Res Treat. 2018 02; 167(3):823. PMID: 29063311.
      View in: PubMed
    19. Sorscher S. To the Editor: Predictive Markers and Precision Medicine. J Natl Compr Canc Netw. 2017 10; 15(10):1186. PMID: 28982743.
      View in: PubMed
    20. Sorscher S. Mechanism of Action and Clinical Impact of Ribociclib-Letter. Clin Cancer Res. 2017 09 15; 23(18):5657. PMID: 28916618.
      View in: PubMed
    21. Sorscher S. Current Challenges Associated With Next-Generation Sequencing of Breast Cancer. JAMA Oncol. 2017 09 01; 3(9):1283-1284. PMID: 28520831.
      View in: PubMed
    22. Sorscher S. Letter to the Editor: Implications of BRAF Mutations in dMMR Colorectal Cancers. Curr Treat Options Oncol. 2017 08 10; 18(9):57. PMID: 28795297.
      View in: PubMed
    23. Sorscher S, Ramkissoon S. Next-Generation Sequencing in Order to Better Characterize a BRCA Variant of Uncertain Significance. Case Rep Oncol. 2017 May-Aug; 10(2):634-637. PMID: 28868023.
      View in: PubMed
    24. Sorscher SM. Patients with negative multi-gene panel testing: a back to the future paradox? Fam Cancer. 2017 07; 16(3):459. PMID: 28258424.
      View in: PubMed
    25. Sorscher S, Desnoyers R, Ouyang K, Ramkissoon S. Li-Fraumeni versus Pseudo-Li-Fraumeni Syndrome: Key Insights for Interpreting Next-Generation Sequencing Reports in Patients with Suspected Cancer Predisposition Syndromes. Oncologist. 2017 09; 22(9):1084-1085. PMID: 28592622.
      View in: PubMed
    26. Sorscher S. Anxiety and Hereditary Testing Results. J Genet Couns. 2017 10; 26(5):1162-1163. PMID: 28540620.
      View in: PubMed
    27. Sorscher S. The Significance of Invasive Breast Cancer Associated With Ductal Carcinoma In Situ (DCIS) Compared With Cancer Without Associated DCIS. JAMA Oncol. 2017 05 01; 3(5):708-709. PMID: 28097315.
      View in: PubMed
    28. Sorscher S. Pembrolizumab in Non-Small-Cell Lung Cancer. N Engl J Med. 2017 03 09; 376(10):996-7. PMID: 28276230.
      View in: PubMed
    29. Sorscher S. Treatment Options and Patient Choices on the Basis of Enhanced Pathologic Complete Response. J Clin Oncol. 2017 05 20; 35(15):1746. PMID: 28524776.
      View in: PubMed
    30. Sorscher S. Pathological complete response as a surrogate endpoint. Breast. 2017 06; 33:202. PMID: 27919614.
      View in: PubMed
    31. Sorscher SM. Next-Generation Sequencing of Tumors to Better Estimate the Clinical Significance of Non- BRCA Germline Deleterious Mutations. J Clin Oncol. 2016 12; 34(34):4183. PMID: 27551129.
      View in: PubMed
    32. Sorscher S. Are We Making Personalized Cancer Care Less Personalized? Front Oncol. 2016; 6:220. PMID: 27812510.
      View in: PubMed
    33. Sorscher SM. Estimating risk using multi-gene panel testing; do negative results change the risk? J Hum Genet. 2017 Feb; 62(2):339. PMID: 27734838.
      View in: PubMed
    34. Sorscher S. Palbociclib and tumor suppressor gene activation. Expert Opin Pharmacother. 2016 10; 17(14):1975. PMID: 27552259.
      View in: PubMed
    35. Sorscher S. More Pitfalls Related to Next-generation Sequencing (NGS). Am J Clin Oncol. 2016 08; 39(4):424. PMID: 27465427.
      View in: PubMed
    36. Sorscher S. How important is 'reason' in influencing adjuvant chemotherapy decisions by patients? Expert Rev Anticancer Ther. 2016 09; 16(9):895. PMID: 27442075.
      View in: PubMed
    37. Sorscher S. Understanding the Significance of Mutations in Tumor Suppressor Genes Identified Using Next-Generation Sequencing: A Case Report. Case Rep Oncol. 2016 May-Aug; 9(2):328-30. PMID: 27462233.
      View in: PubMed
    38. Sorscher SM, Pilarski R, Daly M. Correspondence. J Natl Compr Canc Netw. 2016 05; 14(5):l-li. PMID: 27160237.
      View in: PubMed
    39. Sorscher SM. Discussing the Implications of Genetic Testing With Patients. J Clin Oncol. 2015 Dec 10; 33(35):4231-2. PMID: 26371142.
      View in: PubMed
    40. Sorscher S. Coexisting KRAS and NRAS mutations in colon cancer. J Clin Pathol. 2015 Dec; 68(12):1044. PMID: 26243064.
      View in: PubMed
    41. Sorscher S. Incidental Findings Implying an Inherited Cancer Syndrome from Advanced Tumor Sequencing. J Thorac Oncol. 2015 Aug; 10(8):e77. PMID: 26200285.
      View in: PubMed
    42. Sorscher S. A case of squamous cell carcinoma of the skin due to the molecularly confirmed Lynch Syndrome. Hered Cancer Clin Pract. 2015; 13(1):12. PMID: 25995776.
      View in: PubMed
    43. Sorscher S. RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer-Letter. Clin Cancer Res. 2015 May 01; 21(9):2187. PMID: 25934890.
      View in: PubMed
    44. Cho M, Wang-Gillam A, Myerson R, Gao F, Strasberg S, Picus J, Sorscher S, Fournier C, Nagaraj G, Parikh P, Suresh R, Linehan D, Tan BR. A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma. HPB (Oxford). 2015 Jul; 17(7):587-93. PMID: 25800066.
      View in: PubMed
    45. Rashidi A, Sorscher SM. Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor. Leuk Lymphoma. 2015; 56(8):2468-9. PMID: 25530344.
      View in: PubMed
    46. Sorscher S. Clinical confirmation of an anti-metastasis effect from statins. Int J Biochem Cell Biol. 2014 Dec; 57:207. PMID: 25310901.
      View in: PubMed
    47. Myerson RJ, Tan B, Hunt S, Olsen J, Birnbaum E, Fleshman J, Gao F, Hall L, Kodner I, Lockhart AC, Mutch M, Naughton M, Picus J, Rigden C, Safar B, Sorscher S, Suresh R, Wang-Gillam A, Parikh P. Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):829-36. PMID: 24606849.
      View in: PubMed
    48. Sorscher S. Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab. Cancer Manag Res. 2013; 9:1-3. PMID: 24376362.
      View in: PubMed
    49. Sorscher S. Metastatic pancreatic poorly differentiated neuroendocrine carcinoma: current treatment considerations. Clin Adv Hematol Oncol. 2013 Dec; 11(12):804-5. PMID: 24893287.
      View in: PubMed
    50. Sorscher S. Emil Frei's contributions. J Clin Oncol. 2013 Oct 20; 31(30):3842. PMID: 23878299.
      View in: PubMed
    51. Sorscher S, Saroya B. A molecularly confirmed neuroendocrine tumor resulting from Lynch Syndrome. J Gastrointest Oncol. 2013 Mar; 4(1):95-6. PMID: 23451331.
      View in: PubMed
    52. Sorscher S. Are targeted therapies a consideration in poorly differentiated neuroendocrine tumors? Oncologist. 2013; 18(11):1239. PMID: 24218001.
      View in: PubMed
    53. Sorscher SM. Explaining objective responses to zoledronic acid. Anticancer Drugs. 2012 Nov; 23(10):1121. PMID: 23023113.
      View in: PubMed
    54. Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, Gao F, Linehan D, Wang-Gillam A. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. 2012 Sep 10; 13(5):497-501. PMID: 22964956.
      View in: PubMed
    55. Sorscher SM. Acinar Cell Carcinoma Responding to Carboplatin/Etoposide Chemotherapy. J Gastrointest Cancer. 2012 Sep; 43 Suppl 1:S2-3. PMID: 22058048.
      View in: PubMed
    56. Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, Tan B, Hawkins WG. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs. 2013 Jun; 31(3):707-13. PMID: 22864469.
      View in: PubMed
    57. Sorscher SM, Greco FA. Papillary Renal Carcinoma Presenting as a Cancer of Unknown Primary (CUP) and Diagnosed through Gene Expression Profiling. Case Rep Oncol. 2012 May; 5(2):229-32. PMID: 22679428.
      View in: PubMed
    58. Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Michaud LB, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, Stucky-Marshall L, Todaro B, Urba SG. Antiemesis. J Natl Compr Canc Netw. 2012 Apr; 10(4):456-85. PMID: 22491046.
      View in: PubMed
    59. Sorscher SM, Thomas T. You can't judge a book by its cover or a tumor by its expression profile. Clin Pract. 2012 Jan 01; 2(1):e21. PMID: 24765420.
      View in: PubMed
    60. Sorscher SM. Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal cancer. Cancer Invest. 2011 Aug; 29(7):456-9. PMID: 21696295.
      View in: PubMed
    61. Sorscher SM, Lockhart AC. Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma. J Clin Oncol. 2011 Jul 01; 29(19):2735-6; author reply 2736-8. PMID: 21646612.
      View in: PubMed
    62. Sorscher SM, Hill AE, Belizaire R, Sorscher EJ. Spontaneous inactivating p53 mutations and the "selfish cell". Aging (Albany NY). 2011 Mar; 3(3):181. PMID: 21389353.
      View in: PubMed
    63. Sorscher S. FDA-approved drugs. J Natl Compr Canc Netw. 2010 Dec; 8(12):xxxiv. PMID: 21147898.
      View in: PubMed
    64. Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Markiewicz MA, Nabati L, Nesheiwat C, Rugo HS, Sorscher SM, Stucky-Marshal L, Todaro B, Urba S. Antiemesis. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2009 May; 7(5):572-95. PMID: 19460282.
      View in: PubMed
    65. Sorscher SM. Metastasis in von hippel-lindau disease. J Neurosurg. 2008 Sep; 109(3):568; author reply 568-9. PMID: 18759592.
      View in: PubMed
    66. Sorscher SM, Hill A, Sorscher EJ. Evolutionary maintenance of oncogenesis. J Cancer Res Clin Oncol. 2009 Jan; 135(1):159-62. PMID: 18512072.
      View in: PubMed
    67. Sorscher S, Hill AE, Sorscher EJ. Is oncogenesis a normal cellular defense mechanism? Cancer Chemother Pharmacol. 2008 Nov; 62(6):1113. PMID: 18274747.
      View in: PubMed
    68. Sorscher SM. Hepatocellular carcinoma developing years after extended field radiation for Hodgkin's lymphoma. Acta Oncol. 2008; 47(8):1606-7. PMID: 18607885.
      View in: PubMed
    69. Sorscher SM. Biological therapy update in colorectal cancer. Expert Opin Biol Ther. 2007 Apr; 7(4):509-19. PMID: 17373902.
      View in: PubMed
    70. Sorscher S. 54-year-old man with breast cancer after prolonged testosterone therapy. Clin Adv Hematol Oncol. 2005 Sep; 3(9):713. PMID: 16224445.
      View in: PubMed
    71. Sorscher S, Krause W. 54-year-old man with breast cancer after prolonged testosterone therapy. Clin Adv Hematol Oncol. 2005 Jun; 3(6):475; discussion 476. PMID: 16167025.
      View in: PubMed
    72. Sorscher SM. HER-2 overexpression in breast tumors lacking gene amplification. J Clin Oncol. 2004 Oct 15; 22(20):4232; author reply 4232-3. PMID: 15483038.
      View in: PubMed
    73. Sorscher SM. EGFR mutations and sensitivity to gefitinib. N Engl J Med. 2004 Sep 16; 351(12):1260-1; author reply 1260-1. PMID: 15371587.
      View in: PubMed
    74. Sorscher S, Islam R, Mason A. Urethral 'recurrence' found 14 years after radical cystectomy. Int J Urol. 2004 Jul; 11(7):567-9. PMID: 15242372.
      View in: PubMed
    75. Sorscher SM. Estimating recurrence probability for synchronous breast cancers. Breast. 2004 Jun; 13(3):259-60. PMID: 15177434.
      View in: PubMed
    76. Sorscher SM. Tumor lysis syndrome following docetaxel therapy for extensive metastatic prostate cancer. Cancer Chemother Pharmacol. 2004 Aug; 54(2):191-2. PMID: 15148627.
      View in: PubMed
    77. Sorscher SM. Withdrawal of immunosuppressive therapy after developing melanoma. J Am Acad Dermatol. 2004 May; 50(5):802. PMID: 15097976.
      View in: PubMed
    78. Sorscher S. Elevated parathyroid hormone-related peptide in a patient with an extragonadal germ-cell tumour and hypercalcemia. Can J Surg. 2004 Apr; 47(2):144. PMID: 15132472.
      View in: PubMed
    79. Sorscher SM. Predicting recurrence risk for synchronous primary colon cancers. Clin Adv Hematol Oncol. 2004 Feb; 2(2):122; discussion 122-4. PMID: 16163173.
      View in: PubMed
    80. Sorscher SM. Penile involvement with hand-foot syndrome. Am J Clin Dermatol. 2004; 5(3):209-10. PMID: 15186201.
      View in: PubMed
    81. Sorscher S. 31-year-old female with a prior breast cancer and strong breast cancer family history who continues to menstruate after chemotherapy. Clin Adv Hematol Oncol. 2003 Mar; 1(3):184; discussion 184-5. PMID: 16224403.
      View in: PubMed
    82. Sorscher SM. Electrolyte abnormalities with zoledronic acid therapy. Cancer J. 2002 Jul-Aug; 8(4):348; author reply 348-9. PMID: 12184414.
      View in: PubMed
    83. Sorscher SM. Probable serotonin syndrome variant in a patient receiving a selective serotonin reuptake inhibitor and a 5-HT3 receptor antagonist. J Psychopharmacol. 2002 Jun; 16(2):191. PMID: 12095081.
      View in: PubMed
    Sorscher's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (229) concept(s)
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department
    Physical Neighbors Expand Description
    _